Objective To investigate the effects of different hemostatic methods in laparoscopic ovarian cystectomy on ovary functions . Methods A total of 90 cases of laparoscopic ovarian cyst resection from June 2010 to June 2013 were selected .They were divided into bipolar electrocoagulation group , monopolar electrocoagulation group , and suture group according to the doctor ’ s favor.The FSH, LH, and E2 before and after surgery were compared among the three groups . Results All patients were followed up for more than 1 year.The rate of patients with menstrual disorder in monopolar electrocoagulation group [33.3%(10/30)] was significantly higher than that in bipolar coagulation group [10.0%(3/30),χ2 =4.812,P=0.028] and suture group [6.7%(2/30),χ2 =6.667,P=0.010].There was no significant difference between bipolar premature coagulation group and suture group (χ2 =0.000, P=1.000).There was no significant difference in FSH ,LH,and E2 among the three groups before and 1 month after surgery (P>0.05).There was no significant difference in FSH ,LH, E2 between bipolar premature coagulation group and suture group 6 months after surgery (P>0.05).In the monopolar electrocoagulation group , the FSH [(10.43 ±2.04) U/L] and LH [(18.58 ± 3.82) U/L] levels were significantly higher than those in the bipolar electrocoagulation group [(8.12 ±1.82) U/L and (13.31 ± 2.53) U/L, P<0.05], and in the suture group [(7.08 ±1.68) U/L and (12.61 ±2.68) U/L, P<0.05].The E2 level in the monopolar electrocoagulation group [(252.5 ±26.9) pmol/L] was significantly lower than that in the bipolar electrocoagulation group [(321.3 ±28.2) pmol/L, P<0.05] and in the suture group [(313.7 ±31.4) pmol/L, P<0.05]. Conclusion In laparoscopic ovarian cystectomy , bipolar coagulation hemostasis is safer than monopolar electrocoagulation hemostasis , being worthy of clinical application .

Objective: To systematically analyze the revisions content and technological development trends of microbiological standards in the Chinese Pharmacopoeia (ChP) 2025 Edition, and explore its novel requirements in risk-based pharmaceutical product lifecycle management.
Methods: A comprehensive review was conducted on 26 microbiological-related standards to summarize the revision directions and scientific implications from perspectives including the revision overview, international harmonization of microbiological standards, risk-based quality management system, and novel tools and methods with Chinese characteristics.
Results: The ChP 2025 edition demonstrates three prominent features in microbiological-related standards: enhanced international harmonization, introduced emerging molecular biological technologies, and established a risk-based microbiological quality control system.
Conclusion: The new edition of the Pharmacopoeia has systematically constructed a microbiological standard system, which significantly improves the scientificity, standardization and applicability of the standards, providing a crucial support for advancing the microbiological quality control in pharmaceutical industries of China.